Paras Biopharmaceuticals Finland Oy

PB (RA)-2010 (Rheumatoid Arthritis)

Product Status:

• SDS-PAGE high Expressions
• Separation and purification of Diabrid^™ achieved
• Confirmation through mass spectrometry
• Very high yield of product achieved –multiple grams per liter yield of purified material

Technology Status

• Technology ready to be out-licensed for scale-up production.
• Recombinant state E. Coli clone exhibit expression of the Rheumatoid product (EM@39000-Paras Rights Reserved).
• SDA-PAGE-Gel image showing marker (lane 1), homogenization broth (lane 2) and separation of product (lane 3). Lanes 4 & 5 show the purified product.
• Mass spectrometry (MS) data shows confirmation of the correct product.
• Multiple batches carried out at small & large scales.
• Processes optimized at scale-up level
• Extensive product characterization done
• Biocomparability methods established
• Biosimilarity established